(Iso)-BMT-124110 Formate NEW
Price | $195 | $430 | $636 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: (Iso)-BMT-124110 Formate | Purity: 99.07% |
Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | (Iso)-BMT-124110 Formate |
Description | (Iso)-BMT-124110 Formate has an inhibitory effect on the protein serine/threonine kinase AAK, and is used in the treatment of Parkinson's disease, schizophrenia, neuropathic pain, and Alzheimer's disease. |
Storage | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (201.84 mM) |
Keywords | 1679370-98-9 Free base | 1679370-98-9 | (Iso)-BMT 124110 Formate | (Iso)-BMT-124110 Formate | (Iso)-BMT124110 Formate |
Inhibitors Related | RSS0680 | LP-922761 | SM1-71 | BMT-124110 | BMS-986176 | SGC-AAK1-1 | BMT-124110 Formate | LP-935509 |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$195.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$7.00/1KG |
VIP1Y
|
Hebei Longbang Technology Co., Ltd
|
2024-05-17 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY